Ambica Agarbathies Aroma & Industries Limited Overview
Ambica Agarbathies Aroma & Industries is an 80-year-old, family-controlled South Indian incense house that has been listed since its 1996 public issue. The family describes it as the first agarbatti company to list on Indian exchanges. Its core franchise is the green-branded "Ambica" range of herbal and masala incense, led by Durbar Bathi, a hand-rolled stick launched in the mid-1950s that uses natural resins and 63 herbs. The range also includes dhoop sticks, sambrani cups, camphor and allied pooja products. The brand is strongest in Andhra Pradesh, Telangana and Tamil Nadu. A capital-heavy hospitality arm sits alongside the incense business: the 84–90-room Ambica Empire hotel in Vadapalani, Chennai, and an operation in Visakhapatnam. In FY2026 this arm absorbed about half of total assets and most of the company's debt. Revenue was ₹141 crore in FY2026, but net profit was only ₹3.4 crore, interest cover is thin and the stock trades at about 0.37x book value. The equity story is therefore a debate about brand value versus balance-sheet drag.
Company's own description (Annual Report FY2025-26, MD&A)
The MD&A says the company manufactures and sells incense sticks in India and operates hotels in Chennai and Visakhapatnam. It also says the company is involved in film production and distribution. It describes the business as founded in 1946 and based in Eluru, West Godavari district, Andhra Pradesh. The MD&A states that incense counts for "more than 80% of the revenue in overall turnover". It names Durbar Bathi, Amrutham (Herbal Bathies) and Athisaya (spelled "Athjisaya") Dhoop as its major products. For the hotel division, the company says it caters to business travellers, tourists and event clientele through "a mix of luxury, mid-scale, and budget properties".
On markets, the MD&A says domestic incense sales split roughly 35% South India, 30% West, 18% North and 17% East. It says about 61% of domestic consumption is rural, and that "about 90 foreign countries are using our Agarbathies". That claim sits awkwardly with the same report's disclosure of NIL foreign exchange earnings for FY2026.
Independent characterisation
In economic terms Ambica is three businesses under one listed shell:
-
A branded consumer-staples incense business (about 77% of FY2026 total income). This is a regional FMCG franchise with real brand equity in the Telugu states and Tamil Nadu. ICRA noted in 2018 that the Ambica brand is well established in Andhra Pradesh, Telangana and Tamil Nadu. The business is changing shape. In FY2026, purchases of stock-in-trade were ₹78.89 crore, or 56% of revenue from operations. Raw materials consumed were only ₹20.17 crore. In FY2025 the figures were ₹58.43 crore (47%) and ₹25.44 crore. Ambica is therefore increasingly a brand owner, sourcing and trading finished or semi-finished incense from third parties, rather than a vertically integrated hand-rolling manufacturer. This lowers capital intensity but compresses gross margin. Gross margin fell from 31.6% in FY2025 to 30.0% in FY2026.
-
A single-asset hospitality business (about 23% of FY2026 total income). The core asset is Ambica Empire, a 3.5–4-star business and medical-tourism hotel in Vadapalani, Chennai. The family also cites Ambica Sea Green in Visakhapatnam, a 40-room property. The segment holds ₹124.14 crore of assets, which is 50.7% of the total. It carries ₹105.60 crore of segment liabilities, which is 80% of total liabilities. It reported a pre-tax segment loss of ₹1.08 crore in FY2026. Most of the company's interest burden sits here.
-
Legacy and ancillary activities. These include film production and distribution, wind power generation, a farmland resort with club house and health centre, and real estate or construction. None of these is a reported segment. Their financial contribution is not separately disclosed.
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | About 77% product sales (incense, dhoop, sambrani, camphor) and about 23% services (room nights, food & beverage, banqueting/MICE). No subscription or licensing income disclosed |
| Value-chain position | Brand owner and partial manufacturer in incense. Hand-rolled herbal lines are made in-house. Commodity lines are increasingly bought in. In hospitality, the company is owner-operator (no third-party brand management disclosed) |
| Customers | Incense: distributors and stockists, then general trade and kirana retail; also modern trade and e-commerce (BigBasket lists 17 SKUs). Hotel: corporate travellers, medical tourists (the hotel is near SIMS and Apollo hospitals), wedding and MICE clientele |
| End-markets | Indian household religious consumption (structural, low-cyclicality); Chennai urban hospitality (cyclical) |
| Go-to-market | Distributor network built since 1969 across AP and Telangana. Family claims pan-India presence and exports to Europe and Latin America through a separate export line (Sugandh India, Oct 2025) |
Strategy
Stated strategy
| Theme | Company language / evidence | Analyst assessment |
|---|---|---|
| Plough back profits; no dividend | Board does not recommend a dividend because profits "are planned to be ploughed back into the business operations" (Directors' Report FY2026) | Consistent with negative FCF; no capital-return policy |
| Overseas expansion | "The company plans to explore and tap overseas markets… new products… first launched in the domestic markets and then… overseas" (Annexure I FY2026) | Aspirational; NIL forex earnings in FY2026 |
| Scalable platforms and processes | MD&A (HR section) refers to "building robust platforms and implementing scalable processes" | Generic language, no quantified programme |
| Hospitality positioning | MD&A expects FY2025-26 to be a year of "consolidation and strategic expansion" for hotel operators, driven by domestic leisure, spiritual tourism, MICE and weddings | No company-specific capex or expansion plan disclosed |
| Herbal / traditional brand identity | Family emphasis on herbal products, green branding, hand-rolled quality and BIS certification of agarbatti | Credible brand moat in the South |
| Promoter capital support | Preferential issue of ₹2.12 crore to promoter group for working capital (May–Aug 2026) | Small relative to ₹88 crore debt; signals promoter commitment but not a balance-sheet fix |
The company publishes no investor day, presentation or formal strategy document. Strategic themes are drawn from the Annual Report FY2026 and promoter statements.
Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Detail | Status |
|---|---|---|---|
| FY2025–FY2026 | Shift toward traded / outsourced incense | Stock-in-trade purchases rose from ₹58.43 crore (FY2025) to ₹78.89 crore (FY2026) | Ongoing (inferred from financials) |
| 30 May 2026 | Preferential equity raise | 8,48,600 shares; initially ₹24, revised to ₹25 per share; ₹2.12 crore; for working capital; 3-month utilisation window | Approved at EGM 30 Jun 2026; allotment approved 25 Aug 2026 |
| 2025–26 | Industry leadership | Family member Ambica Ramanjaneyulu as AIAMA President; promoting BIS standards for agarbatti | Ongoing |
| Sep 2023 (outside window, relevant) | Hotel renovation | Ambica Empire complete renovation | Completed |
Sustainability and ESG commitments
None disclosed. CSR under Section 135 is "not applicable". No BRSR is filed. No targets.
Cost programmes
None announced.
Medium-term financial targets / guidance
None. The company provides no revenue, margin or leverage guidance.
Products & Services
Agarbathies Division
| Product / brand | Description & specifications | Target customer | Launch | Indicative price / pack | Source |
|---|---|---|---|---|---|
| Ambica Durbar Bathi (flagship) | Green, hand-rolled herbal masala stick made with natural resins and 63 herbs; marketed as "homam in a stick"; long-burning | Devotional households, South India core | c.1953–55 | ₹75 / 125 g; ₹145 / 220 g | Annual Report FY2026; Sugandh India; BigBasket |
| Ambica Javaji Bathi | The company's first brand; javaji (civet-type) fragrance | Traditional devotional | 1,946 | — | Sugandh India |
| Amrutham (Herbal Bathies) | Herbal incense range in multiple fragrances, natural base materials | Herbal / premium devotional | — | — | Annual Report FY2026 |
| Athisaya Dhoop (Dhoop Cups / Dhoop Sticks) | Dhoop cups and dhoop sticks; very high review volume online | Mass devotional | — | ₹90 / 12 cups; ₹22 / 65 g sticks | Annual Report FY2026; BigBasket |
| Ambica Baba Aarti / Baba Harathi Flora Batti | Herbal flora batti | Devotional | — | ₹105 / 175 g | Sugandh India; BigBasket |
| Ambica Gow Pooja (Panchagavya) | Natural herbal stick made with panchagavya (cow-derived ingredients) | Traditional / ritual users | — | ₹58 / 70 g | Sugandh India; BigBasket |
| Ambica Bangaram | Herbal agarbatti brand | Devotional | — | — | Sugandh India |
| Ambica Heaven | Premium fragrance stick | Urban / premium | — | ₹80 / 48 g; ₹145 / 90 g | Sugandh India; BigBasket |
| Nitya Pooja (Sandal; 6-in-1) | Daily-use pooja sticks, multi-fragrance pack | Mass daily-use | — | ₹62 / 85 g; ₹65 / 132 g | BigBasket |
| 100% Luckk | Everyday fragrance stick | Mass | — | ₹52 / 70 g | BigBasket |
| Lakshmi Tulasi | Basil-leaf-based natural stick | Devotional | — | ₹80 / 100 g | BigBasket |
| Dhoop Sambrani | Sambrani (benzoin) dhoop | Mass South India | 1,992 | — | Sugandh India |
| Cup Sambrani / Colour Cup Sambrani | Self-burning sambrani cups | Mass, pan-India | 1,996 | — | Sugandh India |
| Pure Camphor (tablets, block) | Pooja camphor | Devotional households | — | ₹275 / 150 g tablets; ₹180 / 100 g block | BigBasket |
| Kum Kum Powder | Natural kumkum | Devotional | — | ₹35 / 100 g | BigBasket |
| Scented agarbattis | Fragrance variants including gulab, strawberry, spicy, sandal, rosemary, rose, oriental, opium, myrrh, lavender and jasmine | Mass and urban | Introduced after 1986 | — | Wright Research profile; Sugandh India |
| Export product line | Separate line for European and Latin American markets | Overseas distributors | — | — | Sugandh India |
The family states that Ambica has about 200–300 products and 20–25 herbal agarbatti brands (Sugandh India, Oct 2025). The SKUs and brands below are confirmed from company filings, retail listings and the promoter interview. Retail prices are BigBasket list prices as observed online (2025–26) and are indicative only. The company does not disclose pricing.
Hotel Division
| Property / offering | Specifications | Target customer | Latest refurbishment | Pricing | Source |
|---|---|---|---|---|---|
| Ambica Empire, Vadapalani, Chennai | 3.5-star on OTAs; the family calls it four-star. Room count varies by source: 84 (event-venue listing), 86 (OTAs), about 90 (family). Five suites; 7 floors; built 1999. Near Vadapalani Metro, SIMS Hospital and Vadapalani Murugan Temple; about 30–33 min from Chennai airport | Business travellers, medical tourists, pilgrims, events | Complete renovation completed Sep 2023 | Dynamic OTA pricing; ADR not disclosed. OTA guest scores 5.6–6.0/10 | Hotels.com / Expedia / Travelocity; SuccessfulMeetings; Wright Research |
| — Banqueting / MICE | 4 meeting rooms (His Highness about 1,800 sq ft, Her Majesty, Citrus Hall, 16 A.D.); about 3,900 sq ft event space; capacity about 460 | Weddings, corporate MICE | — | — | SuccessfulMeetings |
| — F&B | Restaurants: Royal Palate, Green Chillies, Andhra Samskruti; pub | In-house and walk-in | — | — | Wright Research |
| — Wellness | Full-service Ayurvedic spa, steam room, gym | Leisure / medical guests | — | — | OTA listings |
| Ambica Sea Green, Visakhapatnam | About 40 rooms (family statement). The MD&A says the company operates hotels in Chennai and Visakhapatnam. Whether the listed company owns this property, or a family entity does, is not confirmed | Leisure / business | — | — | Sugandh India; Annual Report FY2026 MD&A |
Other (non-segment) activities
| Activity | Detail | Financial disclosure |
|---|---|---|
| Film production & distribution | Upstox's profile says the company produced three feature films and distributed over 500 films. The family says it made "seven to eight movies" | — |
| Wind power generation | Referenced in Screener's key points and in the Annual Report FY2026 MD&A risk section | — |
| Farmland resort | Club house and health centre on owned farmland | — |
| Real estate / construction | Tradomate reports a commercial development partnership with APSRTC in Vizag. not found in filings reviewed | — |
Financial Narrative
FY2022–FY2024: Screener standalone data, rounded to ₹1 crore (PAT and EPS derived from Screener/TipRanks EPS). FY2025–FY2026: company audited results (30 May 2026), converted from ₹ lakh. Blank cells mean not available at comparable granularity in the sources reviewed.
Margins and growth
Revenue CAGR. FY2022–FY2026 (four years): about 5.0%. Screener: 5-year sales CAGR 0%, 3-year 6%, 10-year 3%. Sales peaked at ₹168 crore in FY2020 and FY2026 remains about 16% below that peak.
Commentary. Three features dominate.
Volatile top line: Revenue fell from ₹168 crore (FY2020) to ₹98 crore (FY2024). The causes were COVID disruption to the hotel, the agarbatti industry's shift to imported-stick-free and machine-made supply, and a contraction in trading volumes. It then recovered 44% over two years to ₹141 crore, largely through traded goods.
No operating leverage: EBITDA excluding other income has stayed around ₹10 crore in FY2025 and FY2026 despite revenue growth of 14%, because the incremental revenue was low-margin trading.
Earnings depend on other income: Other income exceeded PBT in every year from FY2022 to FY2026 except FY2024 (when PBT was negative). Without other income, the company would have reported pre-tax losses in FY2025 (–₹2.62 crore) and FY2026 (–₹3.43 crore). FY2026 other income of ₹8.46 crore includes ₹6.88 crore of interest income (cash flow statement). This links to the ₹67.31 crore of "other current financial assets", which appear to be interest-bearing loans or advances.
Finance cost burden: At ₹11.27 crore, finance costs consume 111% of EBITDA excluding other income.
Quarterly trend (INR Cr, Screener standalone)
Q1 FY2027 (June 2026) sales fell 18% YoY to ₹24.65 crore. OPM expanded to 12.8%, the best since Q1 FY2025's 15.3%, and net profit was flat YoY at ₹1.11 crore. TTM sales stand at about ₹136 crore and TTM PAT at about ₹3.42 crore (Screener).
Balance sheet
Commentary. Total borrowings excluding lease rose 18% in FY2026, from ₹75.03 crore to ₹88.45 crore, and are up about 50% on the Screener basis since FY2023. The increase funded a ₹9.45 crore rise in receivables and an ₹11.69 crore rise in other current financial assets, not productive capex (FY2026 capex was only ₹0.71 crore). Cash fell to ₹0.28 crore. Equity is inflated by the FY2018 revaluation reserve (reserves rose by about ₹48 crore that year), so the 0.37x P/B partly reflects a market discount to revalued hotel property rather than a pure margin of safety. Goodwill is nil. There are no business-combination intangibles.
Cash flow
FY2025–FY2026 from the company cash flow statement (30 May 2026 filing). The parsed figures are partially garbled in the PDF; CFO and FCF reconcile to Screener's –₹7 crore and ₹1 crore and –₹7 crore FCF. FY2022–FY2024 from Screener.
Commentary. Cash conversion has collapsed. CFO/EBITDA fell from over 90% in FY2022–FY2024 to 14% in FY2025 and –66% in FY2026. FY2026 working-capital outflows were large: receivables –₹9.45 crore and other current assets –₹12.49 crore. FY2026 investing cash flow was positive only because ₹6.88 crore of interest income is classified there. The company is borrowing to fund working capital and advances while earning interest on those advances. The quality of these advances is the single most important open question for equity holders.
Ratios
ROIC (NOPAT ÷ (equity + net debt)). FY2026: EBIT excluding other income of ₹7.84 crore less tax at 25% gives NOPAT of ₹5.88 crore, against invested capital of ₹200.90 crore, so ROIC ≈ 2.9%. FY2025: NOPAT ₹6.20 crore ÷ ₹182.76 crore gives ≈ 3.4%. ROIC is well below any plausible cost of capital (about 12–14% for an Indian nano-cap), so the company is destroying economic value on a reported basis.
Ratio commentary. Leverage is moderate on book D/E (0.85x) but heavy on cash-earnings measures (net debt/EBITDA excluding OI of about 8.7x). Interest coverage has not exceeded 1.5x in any of the last five years. Working-capital days have more than doubled from FY2020's 72 days. Debtor days jumped from 42 to 61 in FY2026. Screener flags low interest coverage and rising debtor days.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Agarbathies segment revenue incl. allocated other income (INR Cr) | — | 96.59 | 115.84 |
Hotel segment revenue incl. allocated other income (INR Cr) | — | 32.33 | 33.70 |
Total segment revenue = total income (INR Cr) | 103 | 128.92 | 149.54 |
Agarbathies segment result, profit before tax (INR Cr) | — | 2.72 | 6.11 |
Hotel segment result, profit before tax (INR Cr) | — | -0.03 | -1.08 |
Agarbathies segment margin (%) | — | 2.8 | 5.3 |
Hotel segment margin (%) | — | -0.1 | -3.2 |
Agarbathies share of total income (%) | — | 74.9 | 77.5 |
Hotel share of total income (%) | — | 25.1 | 22.5 |
Agarbathies segment assets (INR Cr) | — | 99.15 | 120.71 |
Hotel segment assets (INR Cr) | — | 124.39 | 124.14 |
Agarbathies segment liabilities (INR Cr) | — | 16.34 | 26.53 |
Hotel segment liabilities (INR Cr) | — | 97.92 | 105.60 |
Revenue by Segment
| Metric | Q4 FY2025 | Q3 FY2026 | Q4 FY2026 |
|---|---|---|---|
Agarbathies segment revenue (INR Cr) | 23.57 | 46.61 | 17.33 |
Hotel segment revenue (INR Cr) | 8.81 | 8.61 | 8.33 |
Agarbathies segment PBT (INR Cr) | -1.64 | 0.97 | 2.15 |
Hotel segment PBT (INR Cr) | 1.08 | -0.07 | -0.78 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 116 | 117 | 98 | 123.62 | 141.08 |
Other income (INR Cr) | 1 | 5 | 5 | 5.31 | 8.46 |
Total income (INR Cr) | 117 | 122 | 103 | 128.92 | 149.54 |
Cost of goods sold: materials + purchases + inventory change (INR Cr) | — | — | — | 84.51 | 98.73 |
Gross profit (INR Cr) | — | — | — | 39.11 | 42.35 |
Employee benefit expense (INR Cr) | — | — | — | 7.55 | 9.44 |
Admin & other manufacturing expenses (INR Cr) | — | — | — | 21.31 | 22.74 |
EBITDA excl. other income (INR Cr) | 14 | 8 | 5 | 10.25 | 10.17 |
EBITDA incl. other income (INR Cr) | 15 | 13 | 10 | 15.56 | 18.63 |
Depreciation & amortisation (INR Cr) | 3 | 2 | 2 | 1.99 | 2.33 |
Operating income, EBIT excl. other income (INR Cr) | 11 | 6 | 3 | 8.26 | 7.84 |
Finance costs (INR Cr) | 12 | 9 | 11 | 10.86 | 11.27 |
Profit before tax (INR Cr) | 1 | 3 | -2 | 2.69 | 5.03 |
Tax expense (INR Cr) | — | — | — | 2.20 | 1.58 |
Net profit (INR Cr) | 2.40 | 2.53 | -3.66 | 0.49 | 3.45 |
Other comprehensive income (INR Cr) | — | — | — | 7.51 | 0.00 |
Total comprehensive income (INR Cr) | — | — | — | 8.00 | 3.45 |
EPS basic, on PAT (INR) | 1.40 | 1.47 | -2.13 | 0.29 | 2.01 |
EPS diluted, on PAT (INR) | 1.40 | 1.47 | -2.13 | 0.29 | 2.01 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | — | — | — | 31.6 | 30.0 |
EBITDA margin excl. other income (%) | 12.1 | 6.8 | 5.1 | 8.3 | 7.2 |
Operating (EBIT) margin excl. other income (%) | 9.5 | 5.1 | 3.1 | 6.7 | 5.6 |
Net margin (%) | 2.1 | 2.2 | -3.7 | 0.4 | 2.4 |
Revenue YoY growth (%) | -18.9 | 0.9 | -16.2 | 26.1 | 14.1 |
Other income as % of PBT | 100 | 167 | — | 197 | 168 |
Income Statement and Margin Analysis (%)
| Metric | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
|---|---|---|---|---|---|---|---|---|
Sales (INR Cr) | 33.51 | 36.05 | 31.05 | 30.14 | 34.63 | 54.04 | 22.27 | 24.65 |
Operating profit (INR Cr) | 3.09 | 2.35 | 1.27 | 3.09 | 1.83 | 3.28 | 1.97 | 3.16 |
OPM (%) | 9.22 | 6.52 | 4.09 | 10.25 | 5.28 | 6.07 | 8.85 | 12.82 |
Other income (INR Cr) | 1.42 | 1.51 | 1.33 | 1.74 | 2.14 | 1.19 | 3.39 | 1.98 |
Interest (INR Cr) | 2.84 | 2.93 | 2.44 | 2.72 | 2.32 | 3.07 | 3.16 | 3.00 |
PBT (INR Cr) | 1.25 | 0.51 | -0.57 | 1.52 | 1.24 | 0.90 | 1.37 | 1.47 |
Net profit (INR Cr) | 0.93 | 0.38 | -1.94 | 1.14 | 0.93 | 0.56 | 0.82 | 1.11 |
EPS (INR) | 0.54 | 0.22 | -1.13 | 0.66 | 0.54 | 0.33 | 0.48 | 0.65 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 219 | 204 | 211 | 223.53 | 244.85 |
Property, plant & equipment (INR Cr) | — | — | — | 122.81 | 121.43 |
Right-of-use assets (INR Cr) | — | — | — | 6.91 | 6.53 |
Fixed assets incl. ROU, Screener basis (INR Cr) | 122 | 122 | 120 | 130 | 128 |
Non-current investments (INR Cr) | 8 | 8 | 9 | 9.58 | 11.67 |
Inventories (INR Cr) | — | — | — | 5.14 | 5.29 |
Trade receivables (INR Cr) | — | — | — | 14.16 | 23.61 |
Other current financial assets (INR Cr) | — | — | — | 55.62 | 67.31 |
Cash & cash equivalents (INR Cr) | — | — | — | 1.55 | 0.28 |
Long-term borrowings (INR Cr) | — | — | — | 59.77 | 68.28 |
Short-term borrowings (INR Cr) | — | — | — | 15.26 | 20.17 |
Total borrowings excl. lease (INR Cr) | — | — | — | 75.03 | 88.45 |
Lease liabilities (INR Cr) | — | — | — | 7.18 | 7.36 |
Borrowings incl. lease, Screener basis (INR Cr) | 64 | 63 | 67 | 82 | 96 |
Net debt excl. lease (INR Cr) | — | — | — | 73.48 | 88.17 |
Deferred tax liability, net (INR Cr) | — | — | — | 16.30 | 17.18 |
Total equity (INR Cr) | 102 | 105 | 101 | 109.28 | 112.73 |
Goodwill & intangibles (INR Cr) | — | — | — | 0.01 | 0.00 |
Current assets (INR Cr) | — | — | — | 79.99 | 100.82 |
Current liabilities (INR Cr) | — | — | — | 29.70 | 38.41 |
Working capital (INR Cr) | — | — | — | 50.29 | 62.41 |
Book value per share (INR) | 59.4 | 61.1 | 58.8 | 63.6 | 65.6 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 16 | 8 | 5 | 1.42 | -6.92 |
Capital expenditure (INR Cr) | 0 | 2 | 3 | 8.79 | 0.71 |
Free cash flow (INR Cr) | 16 | 6 | 2 | -7.37 | -7.63 |
Investing cash flow (INR Cr) | 0 | -2 | 2 | -4.62 | 6.30 |
Financing cash flow (INR Cr) | -17 | -7 | -6 | 3.33 | -0.65 |
Interest paid (INR Cr) | — | — | — | 11.55 | 12.01 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (INR Cr) | -1 | 0 | 0 | 0.12 | -1.27 |
CFO / EBITDA, Screener (%) | 112 | 101 | 91 | 14 | -66 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on closing equity (%) | 2.4 | 2.4 | -3.6 | 0.4 | 3.1 |
ROA on closing assets (%) | 1.1 | 1.2 | -1.7 | 0.2 | 1.4 |
ROCE, Screener (%) | 7 | 7 | 5 | 7 | 8 |
Current ratio (x) | — | — | — | 2.69 | 2.62 |
Debt/equity, borrowings incl. lease (x) | 0.63 | 0.60 | 0.66 | 0.75 | 0.85 |
Debt/equity, borrowings excl. lease (x) | — | — | — | 0.69 | 0.78 |
Net debt / EBITDA incl. other income (x) | — | — | — | 4.72 | 4.73 |
Net debt / EBITDA excl. other income (x) | — | — | — | 7.17 | 8.67 |
Interest coverage, EBIT incl. OI / interest (x) | 1.08 | 1.33 | 0.82 | 1.25 | 1.45 |
Asset turnover, revenue / closing assets (x) | 0.53 | 0.57 | 0.46 | 0.55 | 0.58 |
Debtor days (days) | 91 | 60 | 35 | 42 | 61 |
Inventory days (days) | 57 | 10 | 30 | 22 | 20 |
Payable days (days) | 108 | 17 | 71 | 15 | 18 |
Cash conversion cycle (days) | 40 | 53 | -6 | 49 | 63 |
Working capital days (days) | 111 | 162 | 197 | 144 | 161 |
Revenue by Region and Region Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Domestic (India) revenue from operations (INR Cr) | 98 | 123.62 | 141.08 |
Export revenue (INR Cr) | — | — | 0 |
Domestic revenue YoY growth (%) | -16.2 | 26.1 | 14.1 |
Segment Overview
| Segment | Andhra Pradesh / Telangana | Tamil Nadu | Rest of India | Overseas |
|---|---|---|---|---|
Agarbathies | Core heartland: factory at Eluru, distribution network since 1969, brand leadership claimed in South India | Strong (ICRA 2018) | Presence claimed pan-India; not quantified | NIL reported in FY2026 filings. Family claims Europe and Latin America line, possibly via a group entity or merchant exporters |
Hotel | Visakhapatnam property (ownership unconfirmed) | Ambica Empire, Chennai (primary asset) | — | — |
Capital Markets
| Metric | 1-Year | 3-Year | 5-Year |
|---|---|---|---|
Share price CAGR, Screener as of 19 Oct 2026 (%) | -4 | -13 | 5 |
Annualised returns, Kotak Neo as of 13 May 2026 (%) | -14.8 | -2.09 | -6.99 |
Value by Reference Point
| Reference point | Value | Date | Source |
|---|---|---|---|
All-time high | ₹44.40 | 28 Jan 2022 | TradingView |
All-time low | ₹5.70 | 25 Feb 2009 | TradingView |
52-week high / low | ₹29.9 / ₹20.0 | As of 19 Oct 2026 | Screener |
Recent price | ₹25.2 | 19 Oct 2026 | Screener |
Earlier sample prices | ₹29.59 (26 Apr 2024); ₹28.57 (5 Nov 2024); ₹23.89 (13 May 2026); ₹24.80 (6 Aug 2026); ₹23.83 (5 Oct 2026) | — | Equitymaster; 5paisa; Kotak Neo; Torus; IncredMoney |
Beta / volatility | Beta 1.32; daily volatility about 2.96% (TradingView); volatility about 5.27x Nifty (ICICIdirect) | — | TradingView; ICICIdirect |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Market cap (INR Cr) | 43.3 (old share count); about 45.4 (post-allotment) | Screener; derived |
Enterprise value (INR Cr) | about 131.5 | Market cap 43.3 + debt 88.45 – cash 0.28 (FY2026); excludes lease liabilities |
P/E, TTM (x) | 12.7 | Screener (TTM EPS about ₹2.00) |
P/B (x) | 0.37–0.38 | BV ₹65.6 per share |
EV/EBITDA incl. other income (x) | about 7.1 | FY2026 EBITDA ₹18.63 crore |
EV/EBITDA excl. other income (x) | about 12.9 | FY2026 EBITDA ₹10.17 crore |
EV/Sales (x) | about 0.97 | TTM sales about ₹136 crore |
Dividend yield (%) | 0.00 | — |
Share Price & Returns
| Date | Instrument | Shares | Price (INR) | Amount (INR Cr) | Allottees |
|---|---|---|---|---|---|
Aug 2026 | Preferential equity | 848,600 | 25 | 2.12 | Four promoter-group members |
Credit Ratings
| Agency | Rating | Outlook | Date | Status |
|---|---|---|---|---|
ICRA | [ICRA]B on ₹66 crore term loan | Stable | 24 Oct 2018 | Withdrawn 16 Nov 2018 |
Moody's / S&P / Fitch | — | — | — | Not rated |
Current | — | — | — | Annual Report FY2026 states credit rating obtained during the year: "NA" |
Bucket Details
| Bucket | Amount (INR Cr) | Note |
|---|---|---|
Current borrowings (within 12 months, incl. current maturities) | 20.17 | Balance sheet FY2026 |
Non-current borrowings | 68.28 | Balance sheet FY2026 |
Lease liabilities (non-current) | 7.36 | Balance sheet FY2026 |
Longest known maturity | May 2033 | ICRA 2018: term loan March 2018 – May 2033 |
Analyst Conclusions
Management guidance
None quantified. Qualitatively, management expects improving hospitality demand from domestic leisure, spiritual tourism, MICE and weddings, and intends to explore overseas markets and reinvest profits (Annual Report FY2026).
Consensus growth expectations
None (no coverage). Run-rate indicators: TTM sales about ₹136 crore and TTM PAT about ₹3.42 crore. Q1 FY2027 sales fell 18% YoY, but OPM was 12.8%.
Bull case
-
Deep asset discount with an identifiable catalyst. The stock trades at about 0.37x book (₹65.6 BV vs about ₹25 price), with an owned 84–90-room hotel in a prime Chennai metro-connected location. Any monetisation, lease-out or management contract that retires part of the ₹105.6 crore of hotel-segment liabilities could re-rate the equity sharply. Removing the hotel's interest burden alone could more than double PBT, since FY2026 finance costs were ₹11.27 crore.
-
The incense franchise is improving. The agarbathi segment result rose 125% to ₹6.11 crore in FY2026, and Q1 FY2027 OPM reached 12.8%. Herbal heritage brands fit the premium segment's roughly 30% growth, and BIS formalisation favours branded players.
-
Promoter alignment is increasing. Promoters bought new shares at ₹25 (above the current price), lifted their stake to 46.08% and have no pledges. This signals confidence and reduces the risk of a dilutive outside raise.
Bear case
-
No core operating profit after interest. Excluding ₹8.46 crore of other income (mostly ₹6.88 crore of interest), FY2026 shows a pre-tax loss of about ₹3.4 crore. ROIC is about 3%. If the ₹67 crore of advances generating that interest are impaired or related-party in nature, earnings and book value are overstated.
-
Cash burn and rising leverage. CFO was –₹6.92 crore and FCF –₹7.63 crore in FY2026. Debt rose 18% to ₹88.45 crore and cash fell to ₹0.28 crore. Interest cover is 1.45x. The ₹2.12 crore promoter infusion covers about two months of interest.
-
Structural disadvantages. The company has about 1% of a fragmented market dominated in marketing by ITC and Cycle Pure. Its growth is increasingly low-margin trading (gross margin down to 30.0%). R&D is zero and exports reportedly nil. Governance carries key-person risk: a CMD over 75, an all-family executive team, unpaid IDs and error-prone disclosures.
Key catalysts and monitorables (next 12 months)
| # | Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|---|
| 1 | Q2 FY2027 results | Nov 2026 (trading window closed from 1 Oct 2026) | Festive-season agarbathi sales, whether 12%+ OPM holds, hotel segment P&L |
| 2 | Use of the ₹2.12 crore preferential proceeds | Within 3 months of allotment (by about Nov 2026) | Utilisation disclosure; receivable reduction |
| 3 | Composition of ₹67.31 crore other current financial assets | H1 FY2027 balance sheet (Nov 2026) and FY2027 Annual Report | Counterparties, related-party share, interest yield, recoverability |
| 4 | Debt trajectory | Half-year balance sheet | Whether borrowings stabilise below ₹90 crore |
| 5 | Hotel strategy | Any Reg 30 disclosure | Asset sale, lease, brand tie-up, or further capex |
| 6 | Q3 FY2027 comparison vs the ₹54 crore Q3 FY2026 spike | Feb 2027 | Tough base; risk of optically weak YoY revenue |
| 7 | Succession planning | Ongoing | Board changes; elevation of third-generation family members |
| 8 | Export disclosure | FY2027 Annual Report | Any forex earnings |
| 9 | Contingent liabilities and RPT disclosures | FY2027 Annual Report | Updated amounts and AOC-2 details |
| 10 | Liquidity | Ongoing | Daily volumes; promoter creeping acquisitions |
Concluding analyst verdict
Ambica Agarbathies Aroma & Industries is a heritage regional consumer brand tied to a capital-hungry, under-earning hotel. The listed equity reflects the combined result. On the positive side, the Ambica incense franchise is real. Durbar Bathi has sold for about 70 years, the brand is recognised in Andhra Pradesh, Telangana and Tamil Nadu, and the agarbathi segment's pre-tax result more than doubled in FY2026 to ₹6.1 crore. Promoters have stepped up with fresh equity at ₹25, pledged nothing, and own 46%. With the stock at about 0.37x a book value underpinned by an owned Chennai hotel, the theoretical asset-value case is easy to make.
The cash-flow and capital-allocation evidence argues the other way. Consolidated operating earnings do not cover interest: excluding other income, FY2026 was loss-making before tax. Free cash flow has been negative for two years, and borrowings rose to ₹88 crore while cash fell to under ₹0.3 crore. Reported profit depends on interest earned on ₹67 crore of other current financial assets whose counterparties are not disclosed. That single line item, equal to 60% of equity, could determine whether book value is a floor or an illusion. Revenue growth has come mainly from low-margin traded goods. Innovation and R&D are nil, and national competitors outspend the company by orders of magnitude. Governance is family-centred, with an over-75 CMD reappointed to 2029, unpaid independent directors and recurring disclosure errors.
In the meantime, they should demand clarity on the advances book. Absent a catalyst that separates the incense brand from the hotel balance sheet, a low ROIC of about 3% is likely to keep the valuation discount in place. Upgrade triggers would be disclosure and recovery of the advances, debt below ₹70 crore, or a hotel transaction.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | DIN | Tenure | Background / education | Age | Shares held (31 Mar 2026) | FY2026 remuneration (INR) |
|---|---|---|---|---|---|---|---|
Ambica Krishna | Chairman & Managing Director (KMP) | 00,391,898 | Since incorporation (1995); reappointed for 13 Feb 2026 – 12 Feb 2029 | Second-generation promoter; more than four decades in production, purchase and marketing; joined the family business 1967–68 | Over 75 | 13,91,806 | 12,00,000 (salary). Approved going forward: ₹24,00,000 p.a. (₹2,00,000/month) as minimum remuneration |
Ambica Ramachandra Rao | Whole-time Director (KMP) | 01,678,538 | Since 30 Nov 2001; retires by rotation, reappointed at the 31st AGM | Undergraduate; more than two decades in purchase and marketing of agarbathies | 55 (born 26 Feb 1971) | 6,16,950 | Nil |
Satyavathi Perla | Whole-time Director (woman director) | 07,141,289 | Reappointed at 29th AGM (Sep 2024) | Promoter-family member | — | 1,39,989 | 12,00,000 |
Mallikarjunarao Voleti | Independent Director; chairs Audit, NRC and Stakeholders' Relationship Committees | — | — | — | — | 0 | Nil (no sitting fees paid) |
B V Subrahmanyeswarao | Independent Director | — | — | — | — | 0 | Nil |
Chunduru Anjaneya Swamy | Independent Director | 08,810,748 | Reappointed at 30th AGM (26 Sep 2025) | — | — | 0 | Nil |
Alapati (Ambica) Hanuma | Chief Financial Officer | — | — | Promoter-group family member (listed as promoter group in 2019 SAST filing) | — | — | — |
Uma Gayathri | Company Secretary & Compliance Officer | — | — | — | — | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
26 Sep 2025 | Chunduru Anjaneya Swamy reappointed as Independent Director | Second term |
12 Feb 2026 | Ambica Krishna reappointed CMD for three years from 13 Feb 2026 | Ratified at 31st AGM, 29 Sep 2026 |
29 Sep 2026 | Ambica Ramachandra Rao reappointed on retirement by rotation | Routine |
Shareholding Trend
| Holder category | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
Promoters & promoter group (%) | 48.35 | 43.69 | 43.41 | 43.41 | 46.08 |
FIIs (%) | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
DIIs / mutual funds (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Public / retail (%) | 51.66 | 56.29 | 56.58 | 56.58 | 53.91 |
Number of shareholders | 9,116 | 8,680 | 8,830 | 8,335 | 8,351 |
Competitive Landscape
Key Competitors
| # | Competitor | Owner | Scale (latest public) | Positioning vs Ambica | Source |
|---|---|---|---|---|---|
| 1 | Cycle Pure Agarbathies | NR Group (Mysuru) | Group turnover about ₹1,700 crore; about ₹1,000 crore of agarbatti; 75 countries (date of figures not specified) | National leader by value; about 20% of the organised segment; heavy fragrance R&D and marketing | YourStory; Social Samosa (Oct 2025) |
| 2 | Mangaldeep | ITC Ltd | Agarbatti revenue not separately disclosed; ITC says Mangaldeep is No. 1 by volume and No. 2 by value | Deep distribution, top ad spender, premium sub-brand "Prana" | exchange4media (Sep 2025) |
| 3 | Zed Black | Mysore Deep Perfumery House | ₹650 crore turnover (FY2021) | Strong in economy segment and North/Central India | YourStory |
| 4 | Hari Darshan | Hari Darshan Sevashram | About ₹300 crore annual production value | Strong in wet dhoop | YourStory |
| 5 | Moksh | Moksh Agarbatti Co | — | National organised player | ResearchAndMarkets |
| 6 | Forest (incl. Baahubali sambrani cups) | Private | — | Strong in Telangana and AP sambrani cups, overlapping directly with Ambica's home market | Sugandh India (Telangana interview) |
| 7 | Darshan | Private | — | Popular in Telangana | Sugandh India |
| 8 | GT (Tamil Nadu sambrani cups) | Private | — | Competes in sambrani cups in Tamil Nadu | Sugandh India |
| 9 | Cycle "Naivedya" (sambrani cups) | NR Group | Included in #1 | Competes with Ambica Cup Sambrani | Sugandh India |
| 10 | Shri Balaji, Big Bell (Kaccha Bela), Amrutha, Lakshmi | Private | — | Regional economy brands | Sugandh India |
| 11 | Unorganised / local rollers | — | About 30–40% of the market (Social Samosa); the top six hold only about 40% (ITC) | Price competition | Social Samosa; exchange4media |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Ambica Agarbathies (FY2026) | NR Group / Cycle Pure | ITC Mangaldeep | MDPH / Zed Black |
|---|---|---|---|---|
Incense revenue (INR Cr) | about 116 (segment, incl. allocated other income) | about 1000 (agarbatti) | — | 650 (FY2021, total) |
Total revenue (INR Cr) | 141 | about 1700 | ITC group (far larger) | 650 |
Revenue growth (%) | 14.1 | — | — | — |
EBITDA margin (%) | 7.2 excl. OI | — | — | — |
R&D intensity (%) | 0 | Not disclosed (fragrance R&D emphasised) | — | — |
Geographic reach | South India core; NIL reported exports | 75 countries | National; exports | National |
“—” = not publicly disclosed.
Recent Developments
The Annual Report states there were no significant or material orders by regulators or courts and no capital-market penalties in the last three years.



